Diagnosis Related Group Costs in a Regulated Environment Claude Le PenGilles Berdeaux Current Opinion 22 September 2012 Pages: 115 - 120
New Generation Aromatase Inhibitors in Breast Cancer Gerald M. Higa Leading Article 22 September 2012 Pages: 121 - 132
Pharmacoeconomic Considerations in Treating Ovarian Cancer Diane Bodurka-BeversCharlotte C. SunDavid M. Gershenson Review Article 22 September 2012 Pages: 133 - 150
Valuing Health-Related Quality of Life Colin GreenJohn BrazierMark Deverill Review Article 22 September 2012 Pages: 151 - 165
The Costs of Pharmacological Treatment for Major Depression Rosanna TarriconeGiovanni FattoreMauro Percudani Original Research Article 22 September 2012 Pages: 167 - 174
Pharmacoeconomics and Clinical Practice Guidelines Anders AnellPatrick Svarvar Original Research Article 22 September 2012 Pages: 175 - 185
Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza Fred Y. AokiDouglas M. FlemingSally Edmundson Original Research Article 22 September 2012 Pages: 187 - 195
Cost-of-Illness of Epilepsy in Italy Patrizia BertoP. TinuperS. Viaggi Original Research Article 22 September 2012 Pages: 197 - 208
Economic Analysis of Long Term Reversible Contraceptives Ceri J. Phillips Original Research Article 22 September 2012 Pages: 209 - 221
